ALERT: The M&A Class Action Firm Continues Investigating the Merger – CNXC, INDT, HSKA, ADAP
12. April 2023 17:25 ET
|
Monteverde & Associates PC
NEW YORK, April 12, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, SAL, ADAP, BRBW
05. April 2023 16:00 ET
|
Monteverde & Associates PC
NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – ADAP, SAL, BRBW, MLVF
29. März 2023 16:30 ET
|
Monteverde & Associates PC
NEW YORK, March 29, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, ADAP, BRBW, SAL
22. März 2023 16:06 ET
|
Monteverde & Associates PC
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – ADAP, LBC, SAL, BRBW
15. März 2023 16:50 ET
|
Monteverde & Associates PC
NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – LBC, ADAP, BRBW, SAL
08. März 2023 16:00 ET
|
Monteverde & Associates PC
NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
19. Mai 2021 17:00 ET
|
Adaptimmune Therapeutics plc
- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - ...
Adaptimmune Reports First Quarter Financial Results and Business Update
06. Mai 2021 07:30 ET
|
Adaptimmune Therapeutics plc
- Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO - - First preclinical update from HLA-independent TCR (HiT) targeting mesothelin at ASGCT - - Enrollment momentum in...
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
15. Oktober 2020 16:40 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the...
Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients
28. August 2020 10:30 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data...